JP2023539113A5 - - Google Patents
Info
- Publication number
- JP2023539113A5 JP2023539113A5 JP2023512107A JP2023512107A JP2023539113A5 JP 2023539113 A5 JP2023539113 A5 JP 2023539113A5 JP 2023512107 A JP2023512107 A JP 2023512107A JP 2023512107 A JP2023512107 A JP 2023512107A JP 2023539113 A5 JP2023539113 A5 JP 2023539113A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- disorder
- substituted
- alkyl
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067303P | 2020-08-18 | 2020-08-18 | |
| US63/067,303 | 2020-08-18 | ||
| US202063131974P | 2020-12-30 | 2020-12-30 | |
| US63/131,974 | 2020-12-30 | ||
| PCT/EP2021/072898 WO2022038171A1 (en) | 2020-08-18 | 2021-08-18 | Phenethylamine derivatives, compositions, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539113A JP2023539113A (ja) | 2023-09-13 |
| JP2023539113A5 true JP2023539113A5 (https=) | 2024-07-26 |
Family
ID=77564095
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512063A Active JP7802769B2 (ja) | 2020-08-18 | 2021-08-18 | 治療用フェネチルアミン組成物およびその使用方法 |
| JP2023512107A Pending JP2023539113A (ja) | 2020-08-18 | 2021-08-18 | フェネチルアミン誘導体、組成物およびその使用方法 |
| JP2025185299A Pending JP2026041715A (ja) | 2020-08-18 | 2025-11-04 | 治療用フェネチルアミン組成物およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512063A Active JP7802769B2 (ja) | 2020-08-18 | 2021-08-18 | 治療用フェネチルアミン組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025185299A Pending JP2026041715A (ja) | 2020-08-18 | 2025-11-04 | 治療用フェネチルアミン組成物およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20240317704A1 (https=) |
| EP (2) | EP4200290A1 (https=) |
| JP (3) | JP7802769B2 (https=) |
| KR (3) | KR20230051486A (https=) |
| AU (2) | AU2021328671A1 (https=) |
| CA (2) | CA3186359A1 (https=) |
| WO (2) | WO2022038170A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220137081A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| AU2021328671A1 (en) | 2020-08-18 | 2023-02-16 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
| WO2023049480A1 (en) * | 2021-09-25 | 2023-03-30 | Alexander Shulgin Research Institute | Substituted phenylalkylamines |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| AU2023351134A1 (en) * | 2022-09-26 | 2025-05-08 | Alexander Shulgin Research Institute | 2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl)ethan-1-aminium chloride |
| EP4608806A1 (en) * | 2022-10-28 | 2025-09-03 | Cybin IRL Limited | Phenethylamine compounds, compositions, and methods of use |
| EP4727538A2 (en) * | 2023-06-15 | 2026-04-22 | Tactogen Inc. | New formulations for mental disorders or mental enhancement |
| WO2025228547A1 (en) | 2024-05-01 | 2025-11-06 | Cybin Irl Limited | Processes for preparing phenethylamine compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| DE19859684A1 (de) * | 1998-12-23 | 2000-06-29 | Bayer Ag | Verfahren zur Herstellung von Fluor enthaltenden Phenethylaminen sowie neue, Fluor enthalende beta-Iminovinyl- und beta-Iminoethylbenzole |
| JP2002293764A (ja) * | 2001-01-26 | 2002-10-09 | Takeda Chem Ind Ltd | アミノエタノール誘導体 |
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| GT200500284A (es) * | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| WO2006079999A2 (en) | 2006-04-09 | 2006-08-03 | Barth Frederik H | Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist |
| WO2008016677A2 (en) | 2006-08-02 | 2008-02-07 | Auspex Pharmaceuticals, Inc. | Preparation and utility of deuterated amphetamines |
| CN102014995B (zh) | 2007-03-30 | 2015-05-13 | 菲利普莫里斯生产公司 | 用于输送药剂的装置和方法 |
| WO2016040822A1 (en) * | 2014-09-12 | 2016-03-17 | Pinpoint Testing, Llc | Ready-to-constitute analytical platforms for chemical analyses and quantification |
| US11839613B2 (en) * | 2017-05-18 | 2023-12-12 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| CA3132731A1 (en) | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| US20220304980A1 (en) | 2019-07-04 | 2022-09-29 | SW Holdings, Inc | Metered dosing compositions and methods of use of psychedelic compounds |
| CN112430187B (zh) | 2019-08-07 | 2023-01-17 | 北京奇点势能科技有限公司 | 一种α,β-氘代胺类化合物、氘代药物及其制备方法 |
| US11246860B2 (en) | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
| AU2021328671A1 (en) | 2020-08-18 | 2023-02-16 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
| EP4221682A2 (en) | 2020-10-02 | 2023-08-09 | Cybin IRL Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| CA3206432A1 (en) | 2021-02-24 | 2022-09-01 | Mind Medicine, Inc. | Mescaline derivatives with modified action |
| US20220323378A1 (en) | 2021-04-03 | 2022-10-13 | Shawn Joseph | Pharmaceutical Compositions and Methods for Treating Mental Health Disorders and Promoting Neural Plasticity |
| WO2022221942A1 (en) | 2021-04-19 | 2022-10-27 | Betterlife Pharma Inc. | Prevention of drug diversion |
| WO2022225884A1 (en) | 2021-04-22 | 2022-10-27 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psychedelic compounds and uses thereof |
| MX2023014630A (es) | 2021-06-08 | 2024-01-30 | Atai Therapeutics Inc | Activadores de dimetoxifenilalquilamina de receptores de serotonina. |
| WO2022271982A1 (en) | 2021-06-23 | 2022-12-29 | Synaptive Therapeutics, Llc | Substituted phenethylamine for treating inflammation and psychological disorders |
| EP4366729A4 (en) | 2021-07-07 | 2025-06-11 | Arcadia Medicine, Inc. | SAFER PSYCHOACTIVE COMPOSITIONS |
| EP4370114A4 (en) | 2021-07-14 | 2025-12-24 | Mydecine Innovations Group Inc | NEW SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS |
| CA3229713A1 (en) | 2021-08-20 | 2023-02-23 | Terran Biosciences Inc. | Deuterated analogs and derivatives of 4-bromo-2,5-dimethoxyphenethylamine and uses thereof |
| JP2024533291A (ja) | 2021-09-08 | 2024-09-12 | サイビン アイアールエル リミテッド | 併用薬物療法 |
| WO2023049480A1 (en) | 2021-09-25 | 2023-03-30 | Alexander Shulgin Research Institute | Substituted phenylalkylamines |
| WO2023156453A1 (en) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
| EP4479373A1 (en) | 2022-02-15 | 2024-12-25 | Cybin IRL Limited | Therapeutic phenethylamine compositions and methods of use |
| CA3246274A1 (en) | 2022-03-31 | 2023-10-05 | Cybin Irl Limited | METHODS OF ADMINISTRATING PSYCHEDELIC MEDICINES BY INHALATION AND SYSTEMS FOR IMPLEMENTING THESE METHODS |
| AU2023242469A1 (en) | 2022-03-31 | 2024-09-05 | Cybin Irl Limited | Combination of nitrous oxide and 5-ht2a receptor agonists |
| EP4608806A1 (en) | 2022-10-28 | 2025-09-03 | Cybin IRL Limited | Phenethylamine compounds, compositions, and methods of use |
-
2021
- 2021-08-18 AU AU2021328671A patent/AU2021328671A1/en active Pending
- 2021-08-18 EP EP21763068.0A patent/EP4200290A1/en active Pending
- 2021-08-18 AU AU2021327136A patent/AU2021327136B2/en active Active
- 2021-08-18 JP JP2023512063A patent/JP7802769B2/ja active Active
- 2021-08-18 WO PCT/EP2021/072896 patent/WO2022038170A1/en not_active Ceased
- 2021-08-18 KR KR1020237003815A patent/KR20230051486A/ko active Pending
- 2021-08-18 US US18/041,728 patent/US20240317704A1/en active Pending
- 2021-08-18 CA CA3186359A patent/CA3186359A1/en active Pending
- 2021-08-18 CA CA3186357A patent/CA3186357A1/en active Pending
- 2021-08-18 EP EP21766581.9A patent/EP4200021A1/en active Pending
- 2021-08-18 WO PCT/EP2021/072898 patent/WO2022038171A1/en not_active Ceased
- 2021-08-18 KR KR1020237006128A patent/KR20230053611A/ko active Pending
- 2021-08-18 US US18/041,731 patent/US12122741B2/en active Active
- 2021-08-18 KR KR1020267007984A patent/KR20260044248A/ko active Pending
- 2021-08-18 JP JP2023512107A patent/JP2023539113A/ja active Pending
-
2024
- 2024-09-05 US US18/825,122 patent/US20240425451A1/en active Pending
-
2025
- 2025-11-04 JP JP2025185299A patent/JP2026041715A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539113A5 (https=) | ||
| JP2023540017A5 (https=) | ||
| JP2025505745A5 (https=) | ||
| JP2023526856A5 (https=) | ||
| JP2025506504A5 (https=) | ||
| JP2022545633A5 (https=) | ||
| JP2024522065A5 (https=) | ||
| JP2023551058A5 (https=) | ||
| JP2021522262A5 (https=) | ||
| KR101580700B1 (ko) | ５-［（３,３,３-트리플루오로-２-히드록시-１-아릴프로필）아미노］-１ｈ-퀴놀린-２-온, 그의 제조 방법, 및 항염증제로서 그의 용도 | |
| JP2024533291A5 (https=) | ||
| AR050902A1 (es) | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion | |
| JP2004511556A5 (https=) | ||
| CN1150803A (zh) | 吡唑并吡啶和吡咯并吡啶 | |
| CA2758474A1 (en) | Novel p2x7r antagonists and their use | |
| JP2023518044A5 (https=) | ||
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| JP2017508733A5 (https=) | ||
| JP2024536863A5 (https=) | ||
| JP2024534111A5 (https=) | ||
| JP2009500425A5 (https=) | ||
| JP2016526023A5 (https=) | ||
| JP2023509944A5 (https=) | ||
| JP2019524752A5 (https=) | ||
| JP2018503647A5 (https=) |